Trelagliptin (succinate)

Trelagliptin (SYR-472) succinate is a potent, orally active and highly selective DPP-4 inhibitor with an IC50 of 4 nM. Trelagliptin succinate improves glycemic control in vivo and can be used for the study of type 2 diabetes mellitus (T2DM) [1].

Product Specifications

CAS Number

[1029877-94-8]

Product Name Alternative

SYR-472 succinate

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Dipeptidyl Peptidase

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/Trelagliptin-succinate.html

Purity

99.96

Solubility

DMSO : ≥ 50 mg/mL|H2O : 100 mg/mL (ultrasonic)

Smiles

O=C(C=C(N1C[C@H](N)CCC1)N2CC3=C(C#N)C=CC(F)=C3)N(C)C2=O.O=C(O)CCC(O)=O

Molecular Formula

C22H26FN5O6

Molecular Weight

475.47

Precautions

H302, H315, H319, H335

References & Citations

[1]Bhumika D Patel, et al. Recent approaches to medicinal chemistry and therapeutic potential of dipeptidyl peptidase-4 (DPP-4) inhibitors. Eur J Med Chem. 2014 Mar 3;74:574-605.|[2]Charles E Grimshaw, et al. Trelagliptin (SYR-472, Zafatek), Novel Once-Weekly Treatment for Type 2 Diabetes, Inhibits Dipeptidyl Peptidase-4 (DPP-4) via a Non-Covalent Mechanism. PLoS One. 2016 Jun 21;11 (6) :e0157509.|[3]Shiliang Li, et al. Discovery of a Natural-Product-Derived Preclinical Candidate for Once-Weekly Treatment of Type 2 Diabetes. J Med Chem. 2019 Mar 14;62 (5) :2348-2361.